FBR Capital Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Raymond James Upgrades Keryx Biopharmaceuticals (KERX) to Outperform
February 26, 2016 7:10 AM ESTRaymond James upgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform with a price target of $6.00.
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $3.34 yesterday.
... MoreJPMorgan Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
February 26, 2016 7:09 AM ESTJPMorgan downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Overweight to Neutral and removed its price target (prior $11.00).
For an analyst ratings summary and ratings history on Keryx Biopharmaceuticals click here. For more ratings news on Keryx Biopharmaceuticals click here.
Shares of Keryx Biopharmaceuticals closed at $3.34 yesterday.
... MoreKeryx Biopharma (KERX) Misses Q4 EPS by 11c
February 25, 2016 7:14 AM ESTKeryx Biopharma (NASDAQ: KERX) reported Q4 EPS of ($0.36), $0.11 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.68 million.
As we enter 2016, the fundamentals of Auryxia are solid, and we plan to... More
